ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO1186

Phase 3 Study to Compare the Efficacy and Safety of Enarodustat (JTZ-951), an Oral HIF-PH Inhibitor, with Darbepoetin Alfa in Anemic Patients with CKD Receiving Maintenance Hemodialysis

Session Information

Category: Anemia and Iron Metabolism


  • Akizawa, Tadao, Showa University School of Medicine, Tokyo, Japan
  • Maeda, Kazuo, Japan Tobacco Inc., Tokyo, Japan
  • Miyazawa, Yuya, Japan Tobacco Inc., Tokyo, Japan
  • Koretomo, Ryosuke, Japan Tobacco Inc., Tokyo, Japan

This phase 3 study was conducted to verify the efficacy (non-inferiority to darbepoetin alfa (DA)) and safety of enarodustat in Japanese anemic patients with CKD receiving maintenance hemodialysis in randomized, double-blind, parallel-arm comparison manner for 24 weeks.


Patients, who have been receiving a stable dose of ESAs and have protocol specified Hb criteria (Hb level of 9.5≥ g/dL and <12.0 g/dL), were randomized in 1:1 ratio to receive either enarodustat orally once daily or DA intravenously every week after switching from ESAs. The doses were adjusted every 4 weeks to maintain Hb levels within a target range (10-12 g/dL). Intravenous iron preparations were prohibited during the screening period and the initial treatment period (Week 0-4). The primary endpoint was difference in mean Hb level between arms during the evaluation period defined as Week 20-24 (non-inferiority margin: -1.0 g/dL). Other assessments included proportion of patients whose Hb level was within the target range and iron-related parameters.


173 patients were randomized to receive either enarodustat (n=87) or DA (n=86). The mean Hb level of each arm during the evaluation period was 10.73 g/dL (95% CI: 10.56, 10.91) with enarodustat arm and 10.85 g/dL (95% CI: 10.72, 10.98) with DA arm. The difference between arms in the mean Hb level was -0.12 g/dL (95% CI: -0.33, 0.10), confirming the non-inferiority to DA. Proportions of patients whose Hb level was within the target range during the evaluation period were 78.2% (95% CI: 67.4, 86.8) in enarodustat arm and 88.8% (95% CI: 79.7, 94.7) in DA arm. Increase of TIBC and decrease of hepcidin were observed through Week 4 in enarodustat arm albeit after switching from ESAs. Proportions of patients who experienced any AEs or SAEs were 87.4% and 14.9% in enarodustat arm and 83.7% and 14.0% in DA arm, respectively.


Enarodustat was proved to be non-inferior to DA in the treatment of anemia in Japanese CKD patients receiving maintenance hemodialysis, and was generally well-tolerated.


  • Commercial Support